MENODYS announces the recruitment of the last patient in a proof of concept comparing its Tinnitus Assessment Technology to the current standard method of evaluating tinnitus

Longueuil, Quebec, Canada – Pr. Sylvie Hébert of the School of Speech Pathology and Audiology at the University of Montreal has completed the recruitment of a proof of concept named MENODYS-INNOV, a research project comparing an innovative technological approach for the objective assessment of tinnitus developed by MENODYS to the standard currently used method of psychoacoustic pitch and loudness measurement used by audiology clinicians around the world. 31 patients with established diagnosis of bilateral tinnitus for at least 6 months were evaluated twice (2 visits) separated by 30 days by 2 different audiologists using during each visit, 2 different methods of evaluation of the tinnitus pitch and loudness. The study objectives are as follow: 1) demonstrating the advantage of the MENODYS tinnitus evaluation method to objectively assess tinnitus in pitch and loudness; 2) demonstrating the advantage of the MENODYS tinnitus evaluation method in terms of time requirement (speed of the test) for the audiologist and the patient; 3) demonstrating the value of assessing high frequencies (above 8000 Hz) in tinnitus assessment procedures; 4) demonstrating the value of the MENODYS tinnitus evaluation method for its capacity to define the best tinnitus symptom attenuation protocol (better adjustment of hearing aids and sound generators); and 5) demonstrating the value of the MENODYS tinnitus evaluation method in terms of test-retest accuracy (a tool to follow–up patients over time on the benefits of tinnitus symptoms attenuation protocols).

“This study was launched to demonstrate the importance for audiology professionals around the world, dealing with tinnitus patients, to have access to a rapid, objective, reproducible, and precise tinnitus assessment technology”, said Richard Côté, Executive Vice President of MENODYS.

Tinnitus is an important and growing worldwide health issue in audiology affecting more than 360 000 Canadians, 30 million Americans and more than 120 million Europeans.